Investor Initiated Studies
At Pentixapharm, we believe that investigator-initiated research (IIR) plays a crucial role in advancing independent clinical and scientific exploration. These studies contribute significantly to expanding the evidence based surrounding our CXCR4-targeted compounds and support the development of innovative diagnostic and therapeutic strategies.
We welcome IIR proposals that aim to improve patient outcomes, close evidence gaps, and explore new theranostic applications.
What we support
We consider investigator-initiated projects in two categories:
Clinical Investigator-Initiated Studies (IIS)
IIS are clinical studies independently designed, initiated, and sponsored by non-Pentixapharm entities such as academic institutions, cooperative groups, or individual investigators. The sponsor-investigator retains full responsibility for study conduct, in compliance with applicable regulations and Good Clinical Practice (GCP).
Investigator-Initiated Non-clinical Research (IINR)– Preclinical and Translational Studies
IINRs encompass laboratory-based or preclinical investigations, including in vivo animal studies and ex-vivo assays. These studies aim to deepen the mechanistic, pharmacological, or technological understanding of Pentixapharm’s compounds or platforms.
Detailed information on supported fields of study, funding opportunities, and requirements can be found in the following document.
Download
Contact IIS
Detailed information on supported fields of study, funding opportunities, requirements and a request template can be found in the documents below.
For any submissions or inquiries regarding clinical IIS proposals, please contact us at iis@pentixapharm.com
For any submissions or inquiries regarding pre-clinical (IINR) proposals, please contact us at preclinicaliis@pentixapharm.com